It's a case of déjà vu as Alzheon pulls IPO again by Phil Taylor Thursday, January 17, 2019 Alzheimer’s drug developer Alzheon has pulled plans for a public listing on the Nasdaq for the second time in nine months.
Second time lucky? Alzheon tries for smaller IPO by Phil Taylor Tuesday, August 28, 2018 After an aborted attempt earlier this year, Alzheon is having another go at an IPO to help fund new trials of its Alzheimer’s candidate tramiprosate.
Alzheon says data back plans for phase 3 program by Phil Taylor Monday, July 23, 2018 Alzheon is still trying to build a case for a pivotal trial of its Alzheimer’s candidate and says new data support its plans.
Just shy of phase 3, Alzheon calls off $81M IPO by Amirah Al Idrus Friday, April 27, 2018 Alzheon had planned to bankroll the phase 3 trial of its once-failed Alzheimer's drug with the IPO funds.
Alzheon files for $81M IPO to fund phase 3 Alzheimer’s trial by Nick Paul Taylor Monday, March 19, 2018 The IPO will equip Alzheon to take its reworking of a once-failed beta amyloid drug into a pivotal trial in a subset of Alzheimer’s patients.
Alzheon’s Alzheimer’s asset boards FDA fast track by Nick Paul Taylor Tuesday, October 24, 2017 The regulatory status sets the prodrug of tramiprosate up to speed through the FDA review process if it bucks the trend and hits the mark in phase 3.
Alzheimer’s biotech Alzheon to move once-failed drug into new PhIII by Ben Adams Monday, July 25, 2016 As the world’s top researchers working in Alzheimer’s disease descend into Toronto for the AAIC this week, all will be coming with a continued show of hope--despite the slew of late-stage failures for the disease over the past decade.
